Dissolvable Microspheres Bring Year-Long Relief to Arthritic Knees
A minimally invasive genicular artery embolization procedure using rapidly resorbable gelatin microspheres eased knee osteoarthritis pain for at least 12 months in a prospective study of 194 patients. The treatment did not replace the joint or require an open operation. Instead, interventional radiologists used a catheter to deliver microscopic particles into selected knee vessels, aiming to calm the abnormal blood vessel growth and inflammatory signaling that can sustain chronic pain.
The effect was durable. Median pain scores on a 0-to-10 Numeric Rating Scale fell from 7 before treatment to 4 at six weeks, then to 3 at six months and remained there at one year. Among patients who completed the pain assessment at 12 months, 80% reached a clinically meaningful improvement threshold. For patients who have already moved through physical therapy, medication, and injections without enough relief, that is not a minor shift; it is a meaningful change in day-to-day mobility.
Why the Knee Becomes a Pain Generator
Osteoarthritis is usually described as cartilage wear, but the pain biology is broader than that. As the protective cartilage layer deteriorates, the joint environment changes: inflammation rises, surrounding tissues remodel, and pain-sensitive nerves become more reactive. In some knees, the synovium and adjacent tissue also develop abnormal hypervascularity, with new vessels and accompanying nerve growth creating a local circuit that can perpetuate discomfort.
That biology explains the logic behind embolization. Rather than trying to rebuild cartilage, the procedure targets the vascular and neuroinflammatory setting around the joint. By reducing blood flow through these abnormal vessels while preserving normal circulation, the intervention aims to quiet the inflamed tissue milieu that keeps signaling pain long after the original joint injury has become chronic.
For patients, the problem is often relentless. Walking, climbing stairs, standing for long periods, and recreational activity can all become harder as knee pain accumulates. Conservative therapy often buys time, but not always enough of it. When joint replacement is not medically suitable, or when patients want to delay surgery, the treatment gap is obvious at the bedside.
A Catheter-Based Procedure Without Joint Replacement
In this study, 114 women and 80 men were treated, with a median age of 69 years and a median body mass index of 28.4. All had persistent symptoms despite at least three months of conventional care, including physical therapy, anti-inflammatory medication, and knee injections. Forty-five participants had arthritis in both knees and underwent two procedures, giving a total of 239 embolizations between July and November 2024.
The technique was superselective. Under fluoroscopic guidance, operators advanced a thin catheter into arteries supplying the painful knee and deployed rapidly resorbable gelatin-based microspheres into the target vessels. The particles are engineered to dissolve within hours, a design intended to combine precise embolization with temporary vessel occlusion rather than permanent obstruction.
All 239 procedures were technically successful.
That matters in a procedure built around selective vascular targeting. A treatment can only work as intended if the catheter reaches the intended arteries, the particles stay where they are meant to go, and the rest of the limb circulation remains intact. The safety profile was reassuring as well: no moderate or severe adverse events were recorded, and mild, temporary complications occurred in 6.7% of procedures. Those events included brief skin discoloration near the treated area and one superficial hematoma at the catheter site, all of which resolved without lasting harm.
Pain Scores, Function, and Quality of Life Moved in the Same Direction
Follow-up remained reasonably strong over the year, with assessments completed by 94% of participants at six weeks, 89% at three months, 89% at six months, and 79% at 12 months. Those visits captured more than pain intensity. Investigators also measured function and quality of life with the Knee Injury and Osteoarthritis Outcome Score, which tracks symptoms, daily activity, sports and recreation, pain, and overall life impact.
Across every domain, scores improved. Daily activity scores rose from 53 to 71.5, suggesting routine movements became easier. Sports and recreation scores increased from 15 to 36, a substantial gain for higher-demand activity. Osteoarthritis symptom scores improved from 51 to 68, pain scores from 44 to 65, and quality of life scores from 19 to 40.
These numbers fit the clinical story patients describe after successful pain intervention: less guarding, more movement, and less mental bandwidth consumed by a single knee. Reduced nociceptive signaling can loosen the cycle in which pain limits movement, deconditioning worsens function, and the joint becomes even more symptomatic.
What the One-Year Data Can and Cannot Prove
The results are encouraging, but they do not answer every question. The study was prospective and single-center, yet it lacked a sham or untreated control group. Without that comparison, it is impossible to determine how much of the improvement came directly from embolizing the blood vessels and how much reflected placebo response, regression to the mean, or the natural course of fluctuating knee pain.
The study also did not show that the procedure slows cartilage loss, reverses structural joint damage, or prevents future knee replacement. The biologic rationale is plausible: reducing inflammatory hypervascularity could theoretically ease the neurovascular drive of pain and perhaps alter local disease activity. Still, plausibility is not proof of disease modification, and this dataset does not establish that claim.
That uncertainty is especially important because other 2026 studies have not pointed in a single direction. A randomized trial comparing embolization plus standard care with standard care alone reported better pain and function with embolization, but used a different embolic material and did not include a sham procedure. By contrast, a sham-controlled study found no significant difference between embolization and sham at 12 months, even though both groups improved. Meta-analytic reviews have similarly found improvements after embolization but questioned whether the benefit exceeds sham effects with enough confidence.
Where Genicular Artery Embolization Fits in Practice
The procedure is attracting attention because it addresses a real clinical problem: patients with persistent osteoarthritis pain who are not good surgical candidates, or who want to postpone arthroplasty. A 2026 position statement from the Society of Interventional Radiology supported offering the technique to carefully selected patients while training, patient selection, and further trials continue to mature.
This study adds an important piece to that conversation because it focused on rapidly resorbable gelatin microspheres, the largest published clinical experience with that specific approach at the time. The durability of the pain reduction through 12 months, paired with the low rate of complications, makes the signal hard to ignore. Yet the next step has to be stricter evidence: larger controlled trials, longer follow-up, and head-to-head comparisons with other embolic materials and with sham procedures.
For now, the procedure sits in a narrow but clinically meaningful space between injections and replacement surgery. It offers a catheter-based option for a joint disease that too often forces patients to choose between temporary relief and major surgery. The remaining question is not whether the knees improved in this cohort. The question is how much of that improvement was truly driven by embolization, and which patients are most likely to benefit from it.